New research highlights the effectiveness of RSV preF vaccines in preventing severe respiratory infections in older adults. RSV is increasingly recognized as a substantial contributor to morbidity and ...
Local News Matters on MSN
Beyond prevention: Routine vaccines deliver surprising health benefits for older adults
The primary reason to be vaccinated against shingles is that two shots provide at least 90% protection against a painful, ...
The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study. The phase 3 randomized controlled trial ...
The shot's efficacy declined slightly compared with the levels of protection after one RSV season, but the new data suggests that the jab generally offers durable protection for adults ages 60 and ...
RSV hospitalization rates in older adults reached 58.3 per 100,000 in winter 2023-24, nearly half the rate of influenza at 114.6 per 100,000. Mortality and clinical outcomes were comparable between ...
A comprehensive new study reveals that respiratory syncytial virus (RSV) vaccines provide strong protection for adults aged 60 and older, with approximately 75% effectiveness against RSV-associated ...
Over the course of a two-day meeting, vaccine advisers to the US Food and Drug Administration voted in favor of approval for RSV vaccines for adults over the age of 60. The vaccine candidates, made by ...
A nationwide Danish cohort study reports cardiovascular events up to 1 year after infection, comparable to that observed with influenza. A nationwide Danish cohort study reports cardiovascular events ...
Researchers found that 47.2% of the 3219 unvaccinated adults had not heard of RSV vaccine or were unsure. HealthDay News — Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine ...
A new shot is helping protect more babies from RSV. A Dayton doctor said it is already dramatically reducing hospitalizations ...
The MarketWatch News Department was not involved in the creation of this content. -- Arexvy will account for the majority share of publicly funded RSV vaccine doses provided in the country for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results